Short Summary
Azurity Pharmaceuticals failed to convince the PTAB that EXELIXIS's drug formulation patent was unpatentable, resulting in a denial of institution for IPR2025-00210. The Board rejected anticipation arguments based on prior art family relationships and dismissed obviousness claims regarding impurity control.
Detailed Summary
The Petitioner, Azurity Pharmaceuticals, Inc., sought to invalidate EXELIXIS, INC.'s patent (11298349) covering drug formulation/process chemistry via Inter Partes Review (IPR). The Board denied institution because the Petitioner failed to demonstrate a reasonable likelihood of success. Specifically, regarding anticipation under 102, the Board ruled that prior art cited from the same patent family did not qualify as effective prior art against the '349 patent. Furthermore, while the Petitioner argued obviousness (103) by combining Brown, Kubo, and Remington to control a specific impurity, the Patent Owner successfully countered this by citing district court findings regarding the lack of motivation for such control under the cited process.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in Azurity Pharmaceuticals, Inc. vs EXELIXIS, INC. is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Luxottica of America Inc. et al.vsE-Vision Optics, LLC
Luxottica has filed an IPR challenging 21 claims of E-Vision Optics' patent regarding embedded electronics in eyewear frames. The petitioner argues that these claims are obvious over decades-old prior art, which discloses generic components and known electronic techniques.
BOE Technology Group Co., Ltd.vsSamsung Display Co., Ltd.
BOE Technology and Samsung Display settled their IPR dispute (IPR2025-01557) before trial. The Board granted a joint motion to terminate, keeping the settlement confidential. No claims were instituted or decided.
Samsung Electronics Co., Ltd. et al.vsWilus Institute of Standards and Technology Inc.
Wilus Institute seeks Director Review to overturn the PTAB’s institution of Samsung’s IPR on patent 11,129,163, arguing the Board misread prosecution history and ignored key arguments about BSS color usage.
Apple Inc.vsCardWare Inc.
Apple has filed an IPR petition challenging all 27 claims of CardWare’s U.S. Patent 11,328,286 covering a dynamic, limited‑use payment card system. The petition alleges obviousness over multiple prior‑art references and argues that printed‑matter limitations lack patentable weight. The case is pending institution.
Samsung Electronics Co., Ltd. et al.vsKannuu Pty. Ltd.
The PTAB granted institution for IPR2026-00071, allowing Samsung Electronics to challenge Kannuu's patent 11573939.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.